UK clinical trial regs are changing — here’s what’s happening
April 14, 2026 | HRA, MHRA, clinical trial
Discover the transformative updates to UK clinical trial regulations, effective from April 2026, and learn how they aim to enhance transparency, participant safety, and trial efficiency.
Change is coming to the UK’s clinical trials landscape – and it’s big. From 28 April 2026, updated Clinical Trial Regulations will come into play, representing the biggest shift in how we plan and deliver clinical trials in the UK in almost two decades.
The amendments, presented by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA), were co-created in partnership with patients, researchers, and industry representatives, and represent a new era in UK clinical research.
The amendments bring the regulations into alignment with current culture. By promoting transparency and clarifying expectations, they aim to enhance participant safety, increase trial diversity, reduce researcher burden, speed up approvals, and position the UK as a trusted global research leader.
Here, we highlight some of the key updates and what they could mean in practice.
1. Updates to language and definitions
One of the most noticeable updates is the modernisation of terminology:
- Definitions have been updated to align with current language and tone:
- ‘Subject’ is now ‘participant’
- ‘Trial site’ is now ‘trial location’
- ‘Amendment’ is now ‘modification’
- There are now three distinct categories of trial modification:
- Substantial modifications
- Modification of an important detail
- Minor modifications
- The definition of Chief Investigator (CI) has been updated to refer to a ‘healthcare professional’. This change means a wider range of registered clinical professions are eligible to act as CIs. Individuals are required to be appropriately qualified through education, training, and experience.
2. Integrated statutory review
Combined Review (MHRA and a Research Ethics Committee) is a system that allows researchers to apply for ethics and regulatory approval at the same time. It has worked in practice for years, but now it’s embedded in the regulations. This means:
- A single integrated submission rather than separate parallel processes
- Faster, clearer decisions and improved communication between stakeholders
- Defined timelines and expectations for regulators and sponsors
For trial teams, this simplifies planning, reduces rework, and supports better alignment between regulatory and ethics considerations.
Initial applications will be made using IRAS. Learn more about the process and whether you need to create an account here.
3. Transparency is now a legal requirement
For the first time, the UK has statutory transparency obligations for all clinical trials of investigational medicinal products (CTIMPs):
- Trials must be publicly registered in a recognised registry
- Results summaries must be published within 12 months
- Plain-language summaries should be offered to participants
This is no longer optional best practice, but law. Trial teams should create standard operating procedures (SOPs) for trial registration, result sharing, and the process of developing timely participant-ready communications.
4. Expectations for trial start and oversight
The updated regulations introduce clearer expectations around when trials should begin and how they should be overseen once approved.
- Trial approvals will no longer remain valid indefinitely. Sponsors are expected to recruit the first UK participant within two years of approval, unless extended
- There is a clearer emphasis on risk-proportionate oversight, meaning the level of monitoring and governance should reflect the level of risk posed by the trial
- Regulatory expectations are more explicitly aligned with international Good Clinical Practice (GCP) principles
For trial teams, this means planning for faster trial start-up and ensuring oversight arrangements are proportionate to the risks involved.
Things to start thinking about
With April just around the corner, you may want to:
- Update your SOPs, playbooks, and templates to reflect the new terminology and processes
- Train your teams on the regulatory changes and what’s expected operationally
- Make sure your quality checks and oversight processes cover the new transparency and trial start rules
- Plan trial registrations and results reporting processes ahead of time
These changes don’t rewrite the basics of ethical, well-run trials, but they do clearly define expectations and bring the UK closer to global standards.
Don’t forget — on the same day as these updated regulations, the latest GCP Guidelines will also take effect in the UK. All clinical trials should comply with the principles of GCP.
If you or your team would like a short briefing slide deck or a practical checklist based on these changes, drop us a line — we are happy to help.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Invited, but not equipped: patient involvement needs more than an open door
Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.
The outcomes are already chosen. So when can patients really shape them?
Explore why involving patients early in Joint Scientific Consultations is critical to shaping the outcomes measured in clinical trials.
Long-term clinical trial engagement is a behavioural challenge – not just an informational one
Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.
Patients are telling the truth — just not to you
Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.
When what matters to patients is hard to measure
Patient-relevant outcomes sit at the heart of the EU HTA reforms, but ensuring they reflect lived experience requires you to look beyond what traditional clinical endpoints measure.
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
A seat at the table: what the EU HTA reforms really ask of patient involvement
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.
Why faster trials make participant understanding more important than ever
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
Older trial participants reject bad design, not technology
Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.
5 key takeaways from the Patient Centricity and Engagement Conference
Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.